Your browser doesn't support javascript.
loading
Pharmacological PAR-1 inhibition reduces blood glucose levels but does not improve kidney function in experimental type 2 diabetic nephropathy.
Waasdorp, Maaike; Florquin, Sandrine; Duitman, JanWillem; Spek, C Arnold.
  • Waasdorp M; Center for Experimental and Molecular Medicine, Amsterdam University Medical Center (UMC), Amsterdam Infection and Immunity Institute, University of Amsterdam, Amsterdam, The Netherlands.
  • Florquin S; Molecular Cell Biology and Immunology, Amsterdam UMC, Amsterdam Infection and Immunity Institute, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; and.
  • Duitman J; Department of Pathology, Amsterdam University Medical Center (UMC), Amsterdam Infection and Immunity Institute, University of Amsterdam, Amsterdam, The Netherlands.
  • Spek CA; Center for Experimental and Molecular Medicine, Amsterdam University Medical Center (UMC), Amsterdam Infection and Immunity Institute, University of Amsterdam, Amsterdam, The Netherlands.
FASEB J ; 33(10): 10966-10972, 2019 10.
Article en En | MEDLINE | ID: mdl-31287960
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Piridinas / Glucemia / Receptor PAR-1 / Nefropatías Diabéticas / Riñón / Lactonas Límite: Animals Idioma: En Año: 2019 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Piridinas / Glucemia / Receptor PAR-1 / Nefropatías Diabéticas / Riñón / Lactonas Límite: Animals Idioma: En Año: 2019 Tipo del documento: Article